Evidence map›Paper›PMID 39856440›Full record

ArticleDrug delivery and translational research2025

Colon delivery of agomelatine nanoparticles in the treatment of TNBS induced ulcerative colitis.

Parinaz Minaiyan, Jaleh Varshosaz, Mohsen Minaiyan

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Parinaz MinaiyanDepartment of Pharmaceutics, Faculty of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0009-0008-3587-9277
Jaleh VarshosazDepartment of Pharmaceutics, Faculty of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran. varshosaz@pharm.mui.ac.ir.ORCID 0000-0001-9333-5798
Mohsen MinaiyanDepartment of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-2129-6299

Funding

Isfahan University of Medical Sciences 3401746
6 · The paper itself

Abstract

Agomelatine is an atypical antidepressant with a long half-life and the mechanism of action similar to melatonin. Agomelatine is a strong antioxidant and its anti-inflammatory effect has been reported in many studies. The current study aimed to evaluate the anti-inflammatory effect of agomelatine loaded in targeted nanoparticles (NPs) in an experimental colitis model induced by trinitrobenzene sulfonic acid (TNBS). Poly(1-vinylpyrrolidone)-graft-(1-triacontene) (PVP-TA) and Eudragit

Indexed as

AcetamidesAnti-Inflammatory AgentsColitis, UlcerativeNanoparticlesAnimalsColonDexamethasoneDisease Models, AnimalDrug LiberationMaleNaphthalenesParticle SizePeroxidasePolymethacrylic AcidsRatsRats, WistarAcetamidesagomelatineAnti-Inflammatory AgentsDexamethasonemethylmethacrylate-methacrylic acid copolymerNaphthalenesPeroxidasePolymethacrylic AcidsTrinitrobenzenesulfonic AcidAnimal modelAntidepressantsDrug deliveryNanoparticlesUlcerative colitis

Identifiers

PMID39856440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.